QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)

ARS Pharmaceuticals (SPRY) News Today

$4.82
+0.14 (+2.99%)
(As of 11/28/2023 ET)
Compare
Today's Range
$4.65
▼
$4.89
50-Day Range
$2.92
▼
$6.61
52-Week Range
$2.55
▼
$9.65
Volume
446,488 shs
Average Volume
982,057 shs
Market Capitalization
$462.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.67
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media
SourceHeadline
MarketBeat logoCritical Analysis: ARS Pharmaceuticals (NASDAQ:SPRY) versus Allarity Therapeutics (NASDAQ:ALLR)
americanbankingnews.com - November 21 at 1:44 AM
benzinga.com logoARS Pharmaceuticals Stock (NASDAQ:SPRY), Analyst Ratings, Price Targets, Predictions
benzinga.com - November 14 at 4:07 PM
finanznachrichten.de logoARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updates
finanznachrichten.de - November 10 at 8:41 AM
finance.yahoo.com logoARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updates
finance.yahoo.com - November 9 at 8:12 PM
benzinga.com logoSHAREHOLDER ALERT: The Law Offices of Vincent Wong Investigate ARS Pharmaceuticals, Inc. (SPRY) for Potential Violations of Securities Laws
benzinga.com - October 12 at 2:26 PM
markets.businessinsider.com logoARS Pharmaceuticals Says FDA Schedules Type A Meeting For Neffy By The End Of October
markets.businessinsider.com - October 6 at 2:22 PM
finance.yahoo.com logoARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy® (epinephrine nasal spray)
finance.yahoo.com - October 6 at 9:20 AM
fool.com logoARS Pharmaceuticals (NASDAQ: SPRY)
fool.com - October 5 at 2:07 PM
benzinga.com logoSHAREHOLDER ALERT: The Law Offices of Vincent Wong Investigate ARS Pharmaceuticals, Inc.(SPRY) for Potential Violations of Securities Laws
benzinga.com - October 3 at 6:53 PM
finance.yahoo.com logoSingle and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical Immunology
finance.yahoo.com - October 3 at 1:53 PM
finance.yahoo.com logoChief Legal Officer Alexander Fitzpatrick Buys 86,258 Shares of ARS Pharmaceuticals Inc
finance.yahoo.com - October 3 at 8:52 AM
finance.yahoo.com logoARS Pharmaceuticals, Harmonic, and More Stocks See Action From Activist Investors
finance.yahoo.com - September 29 at 9:35 PM
finance.yahoo.com logo3 Small Biotech Stocks That Could Be Stars
finance.yahoo.com - September 29 at 11:34 AM
finance.yahoo.com logoWe're Hopeful That ARS Pharmaceuticals (NASDAQ:SPRY) Will Use Its Cash Wisely
finance.yahoo.com - September 28 at 11:45 AM
marketbeat.com logoAvantax Planning Partners Inc. Invests $216,000 in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)
marketbeat.com - September 27 at 6:48 AM
benzinga.com logoFisker, Intercept Pharmaceuticals, Immunovant And Other Big Stocks Moving Higher On Tuesday
benzinga.com - September 26 at 12:13 PM
benzinga.com logoDirector At This Health Care Company Buys $8.18M of Stock
benzinga.com - September 26 at 12:13 PM
msn.com logoARS Pharmaceuticals' EpiPen Alternative Delayed US Approval - Two Analysts Offer Differing Views
msn.com - September 22 at 8:00 AM
marketbeat.com logoARS Pharmaceuticals (NASDAQ:SPRY) Downgraded by Leerink Partnrs
marketbeat.com - September 22 at 6:49 AM
marketbeat.com logoWilliam Blair Analysts Raise Earnings Estimates for ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)
marketbeat.com - September 22 at 6:48 AM
markets.businessinsider.com logoWhat's Going On With ARS Pharmaceuticals Stock Today?
markets.businessinsider.com - September 21 at 8:06 PM
finance.yahoo.com logoARS Pharmaceuticals (SPRY) Down on CRL for Nasal Spray
finance.yahoo.com - September 21 at 3:05 PM
msn.com logoARS Pharma (NASDAQ:SPRY) Plummets on FDA Snub for Epinephrine Nasal Spray
msn.com - September 21 at 10:04 AM
finance.yahoo.com logoFed’s Message Is Louder Than Its Rate Call. Why That’s Critical for Investors.
finance.yahoo.com - September 21 at 10:04 AM
marketbeat.com logoWedbush Cuts ARS Pharmaceuticals (NASDAQ:SPRY) Price Target to $5.00
marketbeat.com - September 21 at 8:46 AM
msn.com logoFDA Declines to Approve Epinephrine Nasal-Spray, Asks for Additional Data
msn.com - September 20 at 6:21 PM
msn.com logoARS Pharma shares plummet after FDA asks for extra test of nasal spray
msn.com - September 20 at 1:21 PM
marketwatch.com logoARS Pharmaceuticals Shares Sink to New Lows on FDA Neffy Setback >SPRY
marketwatch.com - September 20 at 1:21 PM
msn.com logoARS Pharma hits 52-week low as William Blair downgrades on FDA snub
msn.com - September 20 at 1:21 PM
marketbeat.com logo
marketbeat.com - September 20 at 9:48 AM
msn.com logoBiggest stock movers today: Instacart, ARS Pharmaceuticals and more
msn.com - September 20 at 8:21 AM
marketwatch.com logoARS Pharmaceuticals Shares Sink Premarket as FDA Rejects Neffy Spray >SPRY
marketwatch.com - September 20 at 8:21 AM
markets.businessinsider.com logoARS Pharma : FDA Issues CRL For Nasal Spray NDA With Request For Addl Study; Stock Down
markets.businessinsider.com - September 20 at 3:20 AM
reuters.com logoUS FDA declines to approve ARS' emergency nasal spray for allergic reactions
reuters.com - September 20 at 3:20 AM
finance.yahoo.com logoFDA Issues Complete Response Letter for neffy® (epinephrine nasal spray) New Drug Application with Request for Additional Study
finance.yahoo.com - September 20 at 3:20 AM
marketbeat.com logoRoyce & Associates LP Acquires Shares of 303,900 ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)
marketbeat.com - September 13 at 10:43 AM
marketbeat.com logo2,006,451 Shares in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Acquired by Baker BROS. Advisors LP
marketbeat.com - September 12 at 5:40 AM
marketbeat.com logoARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap Up on Insider Buying Activity
marketbeat.com - September 1 at 10:23 AM
msn.com logoARS Pharmaceuticals Prepares For Neffy's Anticipated Launch
msn.com - August 16 at 5:23 PM
finance.yahoo.com logoARS Reports Second Quarter 2023 Financial Results and Provides Business Updates
finance.yahoo.com - August 10 at 5:17 PM
marketbeat.com logoARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Laura Shawver Sells 26,520 Shares
marketbeat.com - July 6 at 11:18 PM
marketbeat.com logoARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Expected to Post Q3 2023 Earnings of ($0.19) Per Share
marketbeat.com - June 23 at 7:54 AM
markets.businessinsider.com logoSVB Securities Sticks to Its Buy Rating for ARS Pharmaceuticals (SPRY)
markets.businessinsider.com - June 22 at 9:07 AM
markets.businessinsider.com logoAnalyst Expectations for ARS Pharmaceuticals's Future
markets.businessinsider.com - June 21 at 1:40 PM
finance.yahoo.com logoARS Pharmaceuticals Announces PDUFA Date Extension for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis
finance.yahoo.com - June 20 at 1:42 PM
marketbeat.com logoLaura Shawver Sells 73,059 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock
marketbeat.com - June 2 at 10:47 PM
marketbeat.com logoQ2 2023 Earnings Estimate for ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Issued By Wedbush
marketbeat.com - May 22 at 1:27 AM
markets.businessinsider.com logoWedbush Keeps Their Buy Rating on ARS Pharmaceuticals (SPRY)
markets.businessinsider.com - May 18 at 7:11 AM
finance.yahoo.com logoARS Pharma (SPRY) Gets FDA Panel Vote for Epinephrine Nasal Spray
finance.yahoo.com - May 15 at 5:46 PM
msn.com logoARS Pharmaceuticals: Potential Revolution In Allergy Treatment With Neffy
msn.com - May 15 at 12:46 PM
Get ARS Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for SPRY and its competitors with MarketBeat's FREE daily newsletter.



SPRY Media Mentions By Week

SPRY Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

SPRY
News Sentiment
▼
0.94

0.87
▲
Average
Medical
News Sentiment

SPRY News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

SPRY Articles
This Week
▼
1

1
▲
SPRY Articles
Average Week

Get ARS Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for SPRY and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:SPRY) was last updated on 11/28/2023 by MarketBeat.com Staff

My Account -